SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE Feb 07, 2022 18:05 HKT/SGT Read More
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 Feb 01, 2022 16:43 HKT/SGT Read More
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma Jan 31, 2022 08:47 HKT/SGT Read More
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases Jan 28, 2022 11:43 HKT/SGT Read More
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM Jan 28, 2022 08:40 HKT/SGT Read More
Labnovation's COVID-19 ART Test Kit, Imported by Clearbridge, one of two COVID-19 ART Test Kits approved by Philippines FDA for Self-Testing Jan 26, 2022 20:45 HKT/SGT Read More
HMI Group Strengthens Specialist Offering, Acquires Majority Stake in Eagle Eye Centre Jan 24, 2022 11:00 HKT/SGT Read More
HMI Group Strengthens Specialist Offering, Acquires Majority Stake in Eagle Eye Centre Jan 24, 2022 11:00 HKT/SGT Read More
エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法について進行性子宮内膜がんを対象とした臨床第III相309試験/KEYNOTE-775試験の結果がthe New England Journal of Medicineに掲載 Jan 20, 2022 09:00 JST Read More
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Jan 20, 2022 08:56 HKT/SGT Read More